- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 11,398
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignancy, Cancer, Oncology, Oncology Patients, Acute Myeloid Leukemia
- Interventions
- AMG 232, Trametinib
- Drug
- Lead sponsor
- Kartos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Buffalo, New York • Charlotte, North Carolina + 2 more
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
- Drug · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 932
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
- Conditions
- Pancreatitis, Acute Necrotizing
- Interventions
- Videoscopic-Assisted Retroperitoneal Debridement (VARD)
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 5
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Hematological Malignancy, Solid Tumor Malignancy
- Interventions
- No Intervention
- Other
- Lead sponsor
- Century Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Los Angeles, California • Baltimore, Maryland + 4 more
- Conditions
- Idiopathic Hypersomnia
- Interventions
- Pentetrazol (PTZ), Placebo oral capsule
- Drug
- Lead sponsor
- Balance Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 28 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, n-aceylcysteine
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 11,850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Promoting Resilience in Stress Management (PRISM)
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Surgery, Non Diabetic Hyperglycemia
- Interventions
- glucose, insulin, and potassium (GIK), Crystalloid Infusion
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Psoriasis, Arthritic
- Interventions
- Ixekizumab, Placebo, Adalimumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
- Conditions
- Lung Cancer
- Interventions
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
- Conditions
- Amyloidosis
- Interventions
- Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
- Conditions
- Carcinoma, Non-small Cell
- Interventions
- Dacomitinib (PF-00299804)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 31
- States / cities
- Orange, California • Pleasant Hill, California • Salinas, California + 15 more
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 27
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- RYZ811, RYZ801
- Diagnostic Test · Drug
- Lead sponsor
- RayzeBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 147
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 9
- States / cities
- La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
- Interventions
- Carboplatin, Cisplatin, Decortication, Intensity-Modulated Radiation Therapy, Pemetrexed, Pemetrexed Disodium, Pencil beam scanning proton therapy, Pleurectomy
- Drug · Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more
- Conditions
- Traumatic Brain Injury, Posttraumatic Stress Disorder
- Interventions
- Cognitively Augmented Behavioral Activation, Treatment as Usual
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
- Interventions
- Pimicotinib(ABSK021), Placebo
- Drug
- Lead sponsor
- Abbisko Therapeutics Co, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more